There Is a Risk of Spread During a Nebulization Session in a Patient with COVID-19.

IF 2 4区医学 Q3 RESPIRATORY SYSTEM

Journal of Aerosol Medicine and Pulmonary Drug Delivery Pub Date : 2023-10-01 Epub Date: 2023-08-22 DOI:10.1089/jamp.2023.0010

Christophe Thibon, Laurent Vecellio, Leila Belkhir, Jean-Christophe Dubus, Annie Robert, Benoît Kabamba, Gregory Reychler

{"title":"There Is a Risk of Spread During a Nebulization Session in a Patient with COVID-19.","authors":"Christophe Thibon, Laurent Vecellio, Leila Belkhir, Jean-Christophe Dubus, Annie Robert, Benoît Kabamba, Gregory Reychler","doi":"10.1089/jamp.2023.0010","DOIUrl":null,"url":null,"abstract":"Introduction: A hypothetical risk of SARS-CoV-2 airborne transmission through nebulization was suggested based on a potential environmental contamination by the fugitive aerosol emitted in the environment during the procedure. The aim of this study was to verify this risk from the fugitive aerosol emitted by COVID-19 patients during one nebulization session. Methods: In this cohort study, COVID-19 patients treated with nebulization were recruited at their admission to the hospital. Patients had to perform a nebulization session while a BioSampler® and a pump were used to vacuum the fugitive aerosol and collect it for SARS-CoV-2 RNA detection. Results: Ten consecutive patients hospitalized with COVID-19 were recruited. The median viral load was 6.5 × 106 copies/mL. Two out of the 10 samples from the fugitive aerosol collected were positive to SARS-CoV-2. Conclusion: The risk of fugitive aerosol contamination with SARS-CoV-2 during nebulization has now been verified.","PeriodicalId":14940,"journal":{"name":"Journal of Aerosol Medicine and Pulmonary Drug Delivery","volume":" ","pages":"268-274"},"PeriodicalIF":2.0000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Aerosol Medicine and Pulmonary Drug Delivery","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1089/jamp.2023.0010","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/8/22 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: A hypothetical risk of SARS-CoV-2 airborne transmission through nebulization was suggested based on a potential environmental contamination by the fugitive aerosol emitted in the environment during the procedure. The aim of this study was to verify this risk from the fugitive aerosol emitted by COVID-19 patients during one nebulization session. Methods: In this cohort study, COVID-19 patients treated with nebulization were recruited at their admission to the hospital. Patients had to perform a nebulization session while a BioSampler^® and a pump were used to vacuum the fugitive aerosol and collect it for SARS-CoV-2 RNA detection. Results: Ten consecutive patients hospitalized with COVID-19 were recruited. The median viral load was 6.5 × 10⁶ copies/mL. Two out of the 10 samples from the fugitive aerosol collected were positive to SARS-CoV-2. Conclusion: The risk of fugitive aerosol contamination with SARS-CoV-2 during nebulization has now been verified.

查看原文本刊更多论文

新冠肺炎患者雾化治疗期间存在传播风险。

引言：根据手术过程中环境中散发的逃逸气溶胶对环境的潜在污染，提出了通过雾化传播严重急性呼吸系统综合征冠状病毒2型的假设风险。本研究的目的是验证新冠肺炎患者在一次雾化过程中释放的逃逸气溶胶的风险。方法：在这项队列研究中，招募接受雾化治疗的新冠肺炎患者入院。患者必须进行雾化治疗，同时使用BioSampler®和泵对逃逸气溶胶进行真空吸尘，并收集其进行严重急性呼吸系统综合征冠状病毒2型RNA检测。结果：招募了连续10名新冠肺炎住院患者。病毒载量中位数为6.5 × 106拷贝/mL。从逃逸气溶胶中采集的10个样本中，有两个对严重急性呼吸系统综合征冠状病毒2型呈阳性。结论：雾化过程中出现严重急性呼吸系统综合征冠状病毒2型无组织气溶胶污染的风险现已得到证实。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Aerosol Medicine and Pulmonary Drug Delivery 医学-呼吸系统

CiteScore

6.70

自引率

2.90%

发文量

审稿时长

>12 weeks

期刊介绍： Journal of Aerosol Medicine and Pulmonary Drug Delivery is the only peer-reviewed journal delivering innovative, authoritative coverage of the health effects of inhaled aerosols and delivery of drugs through the pulmonary system. The Journal is a forum for leading experts, addressing novel topics such as aerosolized chemotherapy, aerosolized vaccines, methods to determine toxicities, and delivery of aerosolized drugs in the intubated patient. Journal of Aerosol Medicine and Pulmonary Drug Delivery coverage includes: Pulmonary drug delivery Airway reactivity and asthma treatment Inhalation of particles and gases in the respiratory tract Toxic effects of inhaled agents Aerosols as tools for studying basic physiologic phenomena.